- Home
- STTK vs SCPH Comparison
STTK vs SCPH Comparison
Compare STTK & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SCPH
- Stock Information
- Founded
- STTK 2016
- SCPH 2013
- Country
- STTK United States
- SCPH United States
- Employees
- STTK N/A
- SCPH N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- SCPH Health Care
- Exchange
- STTK Nasdaq
- SCPH Nasdaq
- Market Cap
- STTK 37.6M
- SCPH 173.6M
- IPO Year
- STTK 2020
- SCPH 2017
- Fundamental
- Price
- STTK $0.83
- SCPH $3.97
- Analyst Decision
- STTK Hold
- SCPH Strong Buy
- Analyst Count
- STTK 4
- SCPH 3
- Target Price
- STTK $3.00
- SCPH $14.00
- AVG Volume (30 Days)
- STTK 401.7K
- SCPH 289.9K
- Earning Date
- STTK 07-31-2025
- SCPH 08-13-2025
- Dividend Yield
- STTK N/A
- SCPH N/A
- EPS Growth
- STTK N/A
- SCPH N/A
- EPS
- STTK N/A
- SCPH N/A
- Revenue
- STTK $4,606,000.00
- SCPH $41,982,000.00
- Revenue This Year
- STTK N/A
- SCPH $108.95
- Revenue Next Year
- STTK N/A
- SCPH $73.83
- P/E Ratio
- STTK N/A
- SCPH N/A
- Revenue Growth
- STTK 69.65
- SCPH 138.10
- 52 Week Low
- STTK $0.69
- SCPH $1.94
- 52 Week High
- STTK $4.99
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- SCPH 61.96
- Support Level
- STTK $0.77
- SCPH $3.77
- Resistance Level
- STTK $0.91
- SCPH $4.08
- Average True Range (ATR)
- STTK 0.08
- SCPH 0.17
- MACD
- STTK -0.02
- SCPH -0.04
- Stochastic Oscillator
- STTK 16.23
- SCPH 76.92
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.